Clinical trial
clinical trial
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Intervention
Drug intervention
Intervention Type
drug intervention
has_intervention
Paclitaxel
drug intervention
Paclitaxel
Intervention
intervention
planned process
planned process
process
occurrent
entity
Contact
has contact
has_contact
Berenberg, Jeffrey
PI
has PI
has_PI
Topic
has topic
has_topic
ovarian cancer
Funded by
funded by
funded_by
Gynecologic Oncology Group
Phase
Phase 2 clinical trial
has phase
has_phase
Phase 2
Performed by
human study performed by
human_study_performed_by
Clinical Protocol & Data Management Shared Resource
http://www.clinicaltrials.gov/ct2/show/NCT00006227?term=GOG-0187&rank=1
ClinicalTrials.gov url
ClinicalTrials.gov url
CTurl
Inhibin
Additional Topic(s)
has_subject_area
The purpose of this study is to estimate the probability of clinical response and toxicity of paclitaxel as second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma, and to evaluate the value of inhibin for predicting response.
Resource Description
resource_description
Patients with histologically confirmed ovarian stromal tumor [granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord stromal tumor, sex cord tumor with annular tubules], and meeting other disease and treatment related criteria.
Study Population
study population
has_study_population
2011-06-29T17:34:05.963-05:00
awendicke (Annemarie Wendicke)
2011-09-23T11:00:59.533-05:00
workflow state
Published
mwilson (Melanie Wilson)
nvasilevsky
Interventional study
Research project
research project
Human Study
human study
human study
planned process
planned process
Quantitative human study
process
occurrent
entity